USA-based Seattle Genetics (Nasdaq: SGEN) is to acquire Cascadian Therapeutics (Nasdaq: CASC) for around $614 million, it was announced on Wednesday.
News of the deal sent the share price of Cascadian, a company formerly known as Oncothyreon that is also based in Seattle, spiraling that morning. It opened 69% up at $9.95. The transaction is anticipated to close in the first quarter of 2018.
Cascadian’s most advanced program is tucatinib, an oral, small molecule tyrosine kinase inhibitor (TKI) that is highly selective for HER2, a growth factor receptor that is overexpressed in multiple cancers, including breast, colorectal, ovarian and gastric.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze